SCHEMBL6718692

SCHEMBL6718692

O=C(O)c1ncc2ccc(Br)cc2c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.42
EGLN2 Q96KS0 2/20 0.40
EGLN1 Q9GZT9 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HTT P42858 1/20 0.39
RXFP1 Q9HBX9 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
PLAT P00750 1/20 0.38
KIT P10721 1/20 0.38
FLT3 P36888 1/20 0.38
NTRK3 Q16288 1/20 0.38
ABL1 P00519 1/20 0.38
CTRC Q99895 1/20 0.37
PRNP P04156 1/20 0.37
PPARG P37231 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25106669 0.87 CTRC (0.42) DHODHEGLN2EGLN1ALDH1A1KDM4E
SCHEMBL522827 0.81 EGLN1 (0.57) EGLN2EGLN1
SCHEMBL8150746 0.76 LDHA (0.50) DHODHEGLN2EGLN1ALDH1A1KDM4E
SCHEMBL520976 0.75 ATM (0.54) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL25274011 0.75 CASP3 (0.42) ALDH1A1KDM4EHTTRXFP1MEN1
SCHEMBL30481274 0.75 CASP3 (0.42) ALDH1A1KDM4EHTTRXFP1MEN1
SCHEMBL6716946 0.73 EGLN1 (0.47) EGLN2EGLN1ALDH1A1MEN1KMT2A
SCHEMBL1034240 0.73 EGLN2 (0.56) EGLN2EGLN1
SCHEMBL8141668 0.73 EGLN2 (0.48) DHODHEGLN2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1034273 0.72 EGLN2 (0.52) EGLN2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180910-A1 Heterocycle carboxamides as antiviral agents SCHNUTE MARK E (US) 2004-09-16 US disclosed
US-6730682-B2 HERPES VIRUS PHARMACIA & UPJOHN COMPANY 2004-05-04 US disclosed
EP-1363907-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-11-26 EP disclosed
US-20020019397-A1 Heterocycle carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-02-14 US disclosed
WO-2002004443-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180910-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 DHODH 459/4885EGLN2 379/4885EGLN1 134/4885
US-20020019397-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 DHODH 459/4885EGLN2 379/4885EGLN1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.